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'"I IE HAVE previo~y documented the long-term per-
V V sistence of donor cell chimerism after successful 
organ transplantation (Tx) and have postulated that it plays 
a seminal role in allograft acceptance and in the induction 
and perpetration of donor-specific tolerance.1•2 To further 
enhance the salutary effects of chimerism we have aug-
mented this phenomenon, since December 1992, by infus-
ing unmodified donor bone marrow (BM) into 190 organ 
allograft recipients; the unavailability of consent to retrieve 
vertebral bodies has resulted in accrual of 110 contempo-
raneous controls. We present here an interim analysis of 
these patients at their most recent follow up. 
MATERIALS AND METHODS 
Patients 
Since December 1992. 183 patients have simultaneously received 
transplants of ABO compatible donor BM and liver (n = 54). 
kidney (n = 35). kidney + pancreas (n = 32). kidney + islets (n = 
7). heart (n = 21). lungs (n = 18). small bowel (n = 13) and 
multi·organ (n = 3). Additionally. since the initiation of a modified 
protocol in April 1996. 7 (liver n = 3. kidney n = 3. kidney + 
delayed islets n = 1) allograft recipients have received multiple 
infusions of donor BM consecutively from days 0 to 4 post Tx. The 
mean follow up was 498 =: 326 days and the mean recipient and 
donor ages were 42 =: 15 and 30 =: 15 years respectively. Further-
more. 110 (liver n = 31, kidney n = 40. heart n = 21. lungs n = 10. 
small bowel n = 7 and multi-organ n = I) allograft recipients for 
whom donor BM was unavailable were monitored as controls. 
Their mean follow up was 552 =: 325 days and mean recipient and 
donor ages were 45 =: 15 and 33 =: 18 years respectively. The 
outcome in BM augmented (n = 8) and non-augmented (n = 2) 
kidney + islet recipients is detailed elsewhere in this issue (see 
Rastellini. et al). 
BM Isolation 
Cells from the wrtebral bodies of cadaveric donors were isolated 
by a method described previously. J In patients receiving a single 
perioperative dose following organ revascularization. 3 to 5 x 10" 
unmodified cells/kg body weight were infused via a central intra-
venous line. In those who received multiple inocula of donor BM. 
I x 10' cells/kg body weight/d were infused consecutively from days 
Il to 4 post Tx. The BM cells used in the latter protocol were 
maintained in culture and not cryopreserved prior to Infusion. 
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Immunosuppression (IS) 
The recipients were not subjected to any cytoablative or cytoreduc-
tive conditioning regimen prior to organ Tx and were maintained 
on routine IS which included tacrolimus and steroids. Minor 
adjustments in the doses of routine IS were made to treat all 
episodes of rejection. Only when steroid-resistant rejection was 
encountered was therapy with a short course of OKT3 or ATG 
deemed necessary. 
In Vitro Studies 
The immune status of the recipient was monitored serially by mixed 
leukocyte reaction. limiting dilution assay. proliferation against 
recall antigens. ConA and PHA; the methodology for which has 
been reported previous/y.4 The results of these assays are reported 
elsewhere in this issue (see Zeevi. et all. For qualitative assessment 
of chimerism. recipients' PBMC were used in which the presence of 
donor cells was detected by cytoftuorography and PCR. Serial 
quantitative evaluations of donor cell chimerism in a selected 
cohort of study and control patients was performed using a 
modified limiting dilution PCR assay. the details of which are 
reported elsewhere.5•6 The multilineage character of chimerism 
was also ascertained by PCR detection of donor DNA in lineage + 
cells sorted from recipients' PBMC. The evidence for the presence 
of donor dendritic cell progenitors and therefore of engraftment 
was obtained by propagation of recipients' PBMC in rhGM-CSF 
and rhIL-4-enriched cultures using a protocol described previous-
ly. 7 Subsequent to enrichment for lineagenUII!MHC class II + pop-
ulation. the presence of donor DNA within the sorted cells was 
confirmed by PCR analysis. 
RESULTS AND DISCUSSION 
The adjuvant 8M infusion was safe and no complications 
uniquely ascribed to this procedure were witnessed in any of 
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Table 1. Graft Function and Percent of BM-Augmented and Nonaugmented Organ Recipients Who Are Off Steroids and Are at 
Least 12 Months Posttransplantation 
Graft Function (X :;: SO) 
Organs Tx 
Uver 
Study 
Control 
Kidney 
Study 
Control 
Heart 
Study 
Control 
Lung 
Study 
Control 
n 
34 
26 
45 
27 
10 
9 
6 
7 
TBili 
rng/dL 
0.5:!: 0.3 
0.3:t 0.2 
Creatinine 
mg/dL 
1.5 :t 0.5 
2.0 :t 0.9 
the 190 organ allograft recipients. All but 17 of 190 (9%) 
BM augmented patients are alive as compared to 131110 
(12%) control recipients. who have died during the course 
of this follow up. It is noteworthy that no deaths in the 
augmented group were related to BM infusion. Addition-
ally, grafts in nine (kidney n = 4, kidney + pancreas n = 1. 
pancreas n = 4) study patients were lost to causes unrelated 
to BM infusion. Similarly grafts in five (kidney n = 1. 
kidney + pancreas n = 1. pancreas n = 3) control patients 
were lost during the course of this follow up. No evidence of 
any complications was witnessed in any of the seven pa-
tients who had received multiple BM infusions during the 
course of their follow-up (19-114 d). All of the surviving 
patients have adequate graft function (Table 1). 
The tempo. severity and cumulative incidencc of rejec-
tion was comparable E~SM%F in the patients in the study 
and control group. Graft versus host disease was only 
witnessed in 2 (1 %) BM augmented recipients (both of 
liver) whose outcome has been reported previously.J In 
patients who are at least 12 months post Tx. a steroid-free 
existence has been achieved in 61 % study and 46% control 
patients. Interestingly. a statistically higher percentage of 
kidney allograft recipients in the study group (71 %) are off 
steroids as compared to that to controls (48%: Table 1). No 
patient is completely off IS. 
Having previously reponed that the incidence of chimer-
ism is much highcr in the study than in the control group;1.,) 
we embarked on developing an assay for its serial quanti-
tative assessment in a selected cohort of study and control 
patients. Using LOA-peR assay. the levels of chimerism 
were found to be at lcast I () to 100 fold higher in BM 
augmented reCipients at up to 2 to J years post-Tx, The 
augmented levels of chimerism in the PBMC uf studv 
patients were indeed ot multilin.:ag.: charact.:r tor the 
Cardiac Output 
(Urnin) 
4.9:t 0.9 
5.0:t 1.2 
FEY, 
(Ll 
1.8:t 0.5 
1.9 :t 0.9 
011 Steroids 
(%l 
23/34 (68) 
18126 (54) 
32/45 (71) 
13127 (48) 
2110 (20) 
119(11) 
1/6 (16.67) 
Ofl(O) 
presence of donor DNA by PCR was confirmed in sorted T 
(CDr), B (CD14+) and NK (CDS6+) cells. Unequivocal 
evidence for BM engraftment was obtained when the 
presence of donor DNA was confirmed within the lin-
eagenull/class II+ cells enriched from colonies harvested 
from cytokine-rich cultures which allows for selective prop-
agation of dendritic cell progenitors. 
Taken together these data suggest that single and multi-
ple perioperative infusion of BM is safe and is associated 
with augmentation of chimerism. Although a higher inci-
dence of steroid-free existence was witnessed in study as 
compared to control patients. it is too early to speculate if 
this observed outcome would sustain itself in a longer 
follow up. It is indeed interesting to note that the salutary 
effects of augmented chimerism on the incidence of evolve-
ment of chronic rejection are already discernible in lung 
transplant recipients for 2 of 7 (29%) surviving control 
patients have evidence for the development of obliterative 
bronchiolitis. a complication yet not witnessed in the study 
population who have a comparable duration of follow up. 
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